According to GlobalData’s medical device pipeline database, 30 Immunohematology devices are in various stages of development globally. GlobalData’s report Immunohematology provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, seven are in active development, while the remaining 24 are in an inactive stage of development. There are three products in the early stages of development, and the remaining four are in the late stages of development.
Immuno haematology studies antigen-antibody reactions and analogous phenomena as they relate to the pathogenesis and clinical manifestations of blood disorders.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Immunohematology pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Immunohematology devices. Overall, most of these Immunohematology pipeline devices are being developed by private entities.
Key players involved in the active development of Immunohematology include Biofortuna, Transfusion & Transplantation Technologies, AliveDx Suisse, Ortho Clinical Diagnostics, SiDx, Amity University, Calviri, Genome Diagnostics, Grifols and AbSorber.
For a complete picture of the developmental pipeline for Immunohematology devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.